I. Company Information

Similar documents
I. Company Information

I. Company Information

I. Company Information

GUIDE HEA

Key Resources in Biomedical Product Development

TAIWAN. Who Should Attend? Endless Potential & Opportunities. Where innovations are shaping a new era of intelligent healthcare.

Start With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development. Paul Docherty PhD Relationship Management

Key Activities. Ofer Reizes, Ph.D. Skills Development Director

Micar Innovation. Drug Discovery Factory for novel drug molecules

CL King Best Ideas Conference

Perspectives on BioPharma Innovation

University of California Center for Accelerated Innovation

KPI Definition Comment Relates to Baseline Target

FDA Regulation of Companion Diagnostics

Stem Cell Research: Identifying emerging high priority policy issues

Imaging not only apoptosis. 30 October 2018 AusBiotech Australia Biotech Invest & Partnering 2018 Dr Barbara Meurer Chief Executive Officer

MARCH 15-16, 2018 PARIS PALAIS BRONGNIART. An event of PROGRAM

Digital Health A PRAGMATIC REGULATORY APPROACH

Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities

Johan Christenson MD; PhD Partner Farmasidagene 2014 Oslo

The Spanish biotech sector Case: ADVANCELL

Career Growth Areas in Physiology / Pharmacology

Course Agenda. Day One

Company Report Daring to be different

February 25, 2019 (Monday) 8:30-16:30 Hrs BioPark Visit (Only for Invitees)

Type of Activity. Universal Activity Number L04-P

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms

REIMAGINING DRUG DEVELOPMENT:

Marina Biotech Monetizes UNA Intellectual Property Estate through Agreement with Arcturus Therapeutics

The International Consortium for Personalised Medicine

A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners Innovation Fund

KRISANI BIO SCIENCES PVT. LTD.

Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015

novel drug molecule for the treatment of Chronic Pain

US FDA: CMC Issues for INDs

Structure and Mandate of FDA

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

Healthcare & Lifesciences Whitepaper

2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award

Presentation Outline

Confronting MedTech Start-Ups Three Biggest Challenges: Initiating Regulatory & Quality

Advancing the Frontiers of mab mixtures

Jefferies Healthcare Conference. June 1, 2015

Erika Smith - Director of the Blavatnik Fund for Innovation at Yale

ABPI response to European Commission consultation on advanced therapy medicinal products

Company Name and Corporate Structure (LLC, B-Corp, C-Corp, etc.): Company Category: Company Size and Stage of Development:

Better Care. Welcome to all-around connected healthcare. March, Septiembre 2017

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY

Precision Medicine & Health Insurance Business Model Disruption? A Data& Evidence perspective

Oversight of Laboratory Developed Tests

L A B O R M A R K E T B R I E F I N G S S E R I E S

INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE!

Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

Promoting the Biotechnology Industry in Germany

Roche, Roche Molecular Diagnostics and more

New Health Data Economy: Strategic Partnerships with Life Sciences Company

Recent Trends in Companion Diagnostic Test Development Partnerships

CDRH Device Approval

PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT

PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT. For personal use only

Nasdaq: MBRX. Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017

Regulatory Market Update: What are the major changes and differences worldwide?

UNIVERSAL ACTIVITY NUMBERS

Phylogica. Harnessing Biodiversity for Peptide Therapies. Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development

Sustainable biotech innovation from an entrepreneur s perspective

Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development

Orthopaedic Innovation: Bench, Bedside, Bank

WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES.

EOS: a Focussed Oncology Company Overview Forum della Ricerca e dell Innovazione Padova, May 16, 2008

Business Plan. Torq Medical. Version 1.0 February 13, Presented by: Axel Chu Liam Sharkey Luke Haliburton

Bipartisan Policy Center, Top Medical Innovation Priorities

GLOBAL CLEANTECH INNOVATION PROGRAMME FOR SMEs IN SOUTH AFRICA. Guidelines for Completing Section Complete Online Application.

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

A Next Generation Stem Cell Therapeutics Company. Investor Presentation: Cynata Therapeutics Limited

Horizon 2020 funding opportunities for Regenerative Medicine ( ) Rudolf Fryček, PhD.

Molecular Diagnostics

About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive

The Next Revolution in Endoscopic Ultrasound Guided Biopsy Products

US Regulatory and Marketing Barriers for Medical Devices

Innovative Medicines Initiative

Phylogica Harnessing biodiversity for biologics discovery

Strategies for attracting healthcare venture capital

Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q

Technology Development Funding Program Round 3

Innovative Partnerships in Biotechnology A Biotech Perspective on Past, Present & Future

FDA Driving Biomedical Product Innovation

Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts

Clinical Trials: Facts and Trends. Dr Nik Nikitin. Founder/Director, Russlan Clinical. ManxBioMed Annual Bio Business Conference 10 th December 2013

Molecular Diagnostics: Market Segmentation and Opportunities

The Right Molecules. Designed. Delivered.

The experience of Andalusia in ehealth and big data --- Big data in health - IMI s HARMONY project, European Parliament, Brussels, 19 June 2018

Sangamo BioSciences Reports First Quarter 2014 Financial Results

博奥信生物技术 ( 南京 ) 有限公司. Biosion (China) Recruiting

CEOCFO Magazine. Dr. Jakub Staszak-Jirkovsky Co-Founder and Chief Executive Officer. Machavert Pharmaceuticals

Novo seeds. Changing the world through entrepreneurship. Oslo Cancer Cluster Summer Meeting. Novo SEEDS

Regulatory Requirements for Medical Devices in China

Tuberculosis Drug Accelerator

Transcription:

Please fill out this form as completely as possible. Note: There is no fee to apply. Please send additional materials such as your pitch deck and executive summary to resi@lifesciencenation.com for us to review along with your application to the RESI Innovation Challenge. *Your Name: *Your Email: *Company Name: *Job Title: *Address: Address2: *City: *State/Province: *Zip/Other Postal Code: *Country: *Phone: *Website: *Industry: I. Company Information *Please Choose your Company Type If you are a Therapeutics company, please fill out form II-A If you are a Medical Devices company, please fill out form II-B If you are a Diagnostics company, please fill out form II-C If you are a Healthcare IT company, please fill out form II-D 1

II-A. Therapeutics-Specific Survey Questions Company description/elevator pitch (80-120 words) Descriptive summary of technology (20 words max) Small Molecule Protein/Peptide Biologic Cell-based Therapy Ab Nucleic Acid (e.g. RNA) Gene Therapy Approach Ab-Drug Conjugate Therapeutic Vaccine Drug Delivery Technology Platform Regenerative Medicine *Drug/technology type (Select all that apply) *Program Stage (Select One) Discovery (candidate seeking) Preclinical Development (Pre-IND Studies) Phase 1 Phase 2 Phase 3 On the Market 2

*Technical Validation achieved to date (Select all that apply) Target Engagement Demonstrated Preclinical Development (pre-ind studies) In Vitro (animal) Activity Acceptable Safety/Tox Profile IND Enabling Safety/Tox Phase 1 Safety Demonstrated Phase 2 Proof of Concept Achieved Standard FDA Approval Process Generic Drug Approval Drug for Rare/Orphan Disease Fast Track Approval Possible/Granted Priority Review Voucher Possible *Regulatory pathway (Select all that apply) 3

II-B. Medtech Devices-Specific Survey Questions Company description/elevator pitch (80-120 words) Descriptive summary of technology (20 words max) Implantable Devices Patient Monitoring Device Imaging Hardware, Tracers, etc Delivery Devices Biomaterials, Coatings Single Use Devices (disposable) Reusable Instrumentation Infection Control In Vitro Diagnostics Companion Diagnostics (theranostics) Patient Aids Wound Care Portable Device Subsector (Select all that apply) *Regulatory pathway (Select all that apply) 510k Pathway for Market Approval 510k Required Premarket Approval Application (PMA) will be required Humanitarian Device Exemption Process (rare diseases) 4

II-C. Medtech Diagnostics-Specific Survey Questions Company description/elevator pitch (80-120 words) Descriptive summary of technology (20 words max) Implantable Devices Patient Monitoring Device Imaging Hardware, Tracers, etc Delivery Devices Biomaterials, Coatings Single Use Devices (disposable) Reusable Instrumentation Infection Control In Vitro Diagnostics Companion Diagnostics (theranostics) Patient Aids Wound Care Portable Device Subsector (Select all that apply) *Regulatory pathway (Select all that apply) 510k Pathway for Market Approval 510k Required Premarket Approval Application (PMA) will be required Humanitarian Device Exemption Process (rare diseases) 5

II-D. Healthcare IT/Digital Health -Specific Survey Questions Company description/elevator pitch (80-120 words) Descriptive summary of technology (20 words max) *Digital health subsector (select one) Consumer Health Self-Management Wearables and Biosensing Care Coordination Electronic Health (EHR) and Medical (EMR) Records Telemedicine and Virtual Care Payer Administration Analytics and Big Data (Including Pt Records) Population Health Non-Regulated Consumer Health Product Other * Market traction (Select One) Free Pilot Paid Pilot Post-Pilot Sales Successful Crowd Funding Sustained Sales 6

III. General Questions for All Industry Sectors *Technology Overview: Briefly describe the technology you are developing. Be sure to describe its ultimate utility and be sure to highlight any new science that enables its development. If Digital Health is your focus, please describe the gap/unmet stakeholder need that will be addressed by your product and how it will be accomplished. (500 words max) *Is your product Iterative (next-gen, incremental improvement, etc.), Breakthrough (new drug target, new use, etc.), or Transformational (novel technology)? (Select One) Iterative (next-gen, incremental improvement, etc.) Breakthrough (new drug target, new use, etc.) Transformational (novel technology) * Technical Validation Achieved to Date: Biotech / Medtech: Describe any data confirming that your technology achieves its intended purpose. (e.g., performance in animal models, device/test performance, platform technology validation, clinical proof-of-concept, etc.) Digital Health: Describe the progress you have achieved to date in gaining market traction with your product. (500 words max) 7

*Have you completed a competitive analysis? (Select One) Yes No *Please provide a list of your competitors. How is your technology differentiated from each competitor? *Can you currently provide data to support your differentiation? If not, what is your time horizon to generate this data? (Select One) Currently Have Data 0-6 Months 7-12 Months 13-18 Months 18+ Months *Company Milestones: Describe key milestones that have been achieved and the projected timeline to the next inflection point for your company. (500 words max) 8

*What is the estimated cost to achieve commercialization? Please provide estimated costs to reach each milestone. *Achieving Market Entry: Briefly describe how your therapeutic, device, technology or digital health product will distinguish itself from current and anticipated competitors in your market segment. How novel is your technology? What, if any, new stakeholder groups are you targeting? (500 words) *What is the expected market size upon approval? Please provide both monetary value and disease prevalence. (500 words) 9

*Alliances & Collaborations: Biotech / Medtech: Highlight any strategic alliances you have established that will enable development, validation, regulatory approval, production or marketing of your technology. Digital Health: Highlight any manufacturing partners engaged, any flagship customer(s) obtained or distribution agreements you have entered into. (500 words) *Please list any valued 3rd party relationships (CRO, Vendors, Distribution Partners, etc.), or n/a if not applicable. Are these relationships regional or global players? (500 words) *IP status (Select all that apply) Patent disclosures at university Patent applications filed Key patent(s) issued Broad IP position established 10

*What university, if any, did you obtain your Tech Transfer License from? (500 words) *Is there a royalty associated with your license? (Select One) Yes No *Do you have global patent protection? If not, what regions are excluded? (500 words) *CEO profile (Select all that apply) Technical Expert Founder/Academic Entrepreneur Management Experience Leading Multiple Companies Successfully Obtained Non-dilutive Funding Successfully Obtained Investment Capital Serial Entrepreneur with Significant Business Experience 11

*Management team in place (Select all that apply) Virtual (CEO only) CSO/CTO CFO Business Development support SAB Established Experienced external advisors *Please list Management Team (Title + Relevant Experience) *Please list Advisory Board (Title + Relevant Experience) *Company financing to date (Select all that apply) SBIR/STTR Angel Seed Series A Series B Series C or later *Are you currently fundraising? (Select One) Actively looking for investment capital Not at Present Time Will be Raising Funds Within 6 Months Will be Raising Funds Within 1 Year 12

*If actively fundraising, what stage of financing are you raising? (Select One) None/ Not Applicable Angel Seed Series A Series B or Later What amount (in millions $USD) are you hoping to raise? Thank you for applying to RESI Innovation Challenge. If you have any questions, please contact RESI@lifesciencenation.com Please send additional materials such as your pitch deck and executive summary to resi@lifesciencenation.com for us to review along with your application to the RESI Innovation Challenge. 13